BMI View : The epidemiological profiles of emerging markets are evolving as economic prosperity is leading to a shift in disease patterns - away from communicable diseases to those associated with lifestyle diseases. In addition to changes in population demographics, including increased urbanisation, smoking, obesity and pollution are the factors most likely to drive morbidity trends in developing nations. In particular, diabetes and cancer pose two of the greatest threats.
Although Bangladesh has made great progress in addressing communicable diseases, conditions such as pneumonia, diarrhoea and malaria are still highly prevalent. As the country's economy develops over the next 10 years, Bangladesh will experience increasing cases of chronic disease, such as obesity and diabetes. According to BMI's Burden of Disease Database (BoDD), communicable diseases and non-communicable diseases accounted for 33.48% and 50.23% of the total disease burden respectively in 2012. However, by 2030, communicable diseases and non-communicable diseases will account for 17.58% and 64.47% of the total disease burden, boosting the demand for high-value therapeutics. In 2012, 28,885,823 disability-adjusted life years (DALYs) were lost to disease in Bangladesh and by 2030 this will decrease marginally to 27,229,382 DALYs.
|A Growing Burden|
|Bangladesh: DALYs Lost To Cancer|
Highlighting a growing demand for medicines to treat chronic diseases, in 2012, there were 1.5mn cancer patients in Bangladesh, up from 1.2mn in 2011, according to the National Institute of Cancer Research and Hospital (NICRH). According to BMI's BoDD, in 2012, 1,034,162 DALYs were lost to malignant neoplasms in Bangladesh, with mouth and oropharynx cancers (25%), trachea, bronchus, lung cancers (15%), cervix uteri cancer (15%), oesophagus cancer (13%) and breast cancer (10%) accounting for the highest burdens.
Revenue Earning Opportunities
In August 2013, it was reported that Bangladesh's cancer therapeutics market is growing at 20% a year due to an alarming rise in cancer patients. Locally-produced drugs meet the majority of the demand (86%), while the remaining 14% is met through imports. Beacon Pharmaceuticals, a Bangladeshi-owned company, is the market leader with a 31% market share, followed by Roche Bangladesh (24%), Sanofi Bangladesh (15%), Techno (14%), Novartis Bangladesh (1%), GSK Bangladesh (1%) and imports by a number of companies (14%).